CO70 Matching Adjusted Indirect Comparison (MAIC) of Single Tremelimumab Regular Interval Durvalumab (STRIDE) Versus Atezolizumab with Bevacizumab (A+B) for the Treatment of Unresectable Hepatocellular Carcinoma (UHCC)

Autor: Qin, L., Chan, S., Le Nouveau, P., Gaughan, A., Gauthier, A., Makowsky, M., Kurland, J., Negro, A., Palmer, S.
Zdroj: In Value in Health June 2023 26(6) Supplement:S27-S27
Databáze: ScienceDirect
Externí odkaz: